Stay updated on Pembrolizumab Combo vs Placebo in Cervical Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo vs Placebo in Cervical Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo vs Placebo in Cervical Cancer Clinical Trial page
- Check4 days agoChange DetectedThe ClinicalTrials.gov page footer now identifies the site as revision v3.8.1 instead of v3.8.0.SummaryDifference0.0%

- Check11 days agoChange DetectedThe record presents the completed KEYNOTE-826 Phase 3 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer, including its design, outcomes, locations, publications, and study documents.SummaryDifference100%

- Check18 days agoChange DetectedThe footer shows an updated ClinicalTrials.gov site revision, from v3.7.2 to v3.8.0. The study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check32 days agoChange DetectedA site-wide NIH notice about the terminology transition from “Artificial Intelligence” to “Super Intelligence” appears above the error page. The site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check46 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

- Check60 days agoChange DetectedAccess to the study record now results in a 403 Forbidden error page, replacing the expected content with an access-denied message.SummaryDifference19%

Stay in the know with updates to Pembrolizumab Combo vs Placebo in Cervical Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo vs Placebo in Cervical Cancer Clinical Trial page.